Hepion (HEPA) Director Michael Purcell Receives 299,000-Share Award

What Happened
Michael J. Purcell, a director of Hepion Pharmaceuticals, received an award of derivative securities covering 299,000 shares on August 19, 2026. The Form 4 reports the grant with an acquisition price of $0.00 (transaction code A), so the filing shows no cash paid for the award itself. This is a grant/award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-08-19; Form 4 filed: 2026-09-10 (filed late relative to the typical two-business-day reporting requirement).
• Transaction code: A (award/grant of derivative securities). Reported acquisition price: $0.00 per share.
• Shares involved: 299,000 derivative shares granted.
• Shares owned following the transaction: not specified in the provided filing details.
• Footnotes/conditions: filing does not disclose vesting schedule, exercise price (if applicable), or 10b5-1 plan; no tax-withholding or sale noted on this Form 4.

Context
Derivative awards (e.g., stock options, restricted stock units) are common compensation for directors and do not by themselves indicate buying or selling sentiment. Such grants often vest over time under a company plan; the Form 4 here does not provide vesting or other plan terms. Note the filing was submitted on Sept 10 for an Aug 19 transaction, which is later than the standard two-business-day window — late filings can occur for administrative reasons but may carry SEC reporting implications.